Risk Factors for Community-Onset Pneumonia Caused by Levofloxacin-Nonsusceptible Streptococcus pneumoniae

被引:8
|
作者
Seok, Hyeri [1 ]
Kang, Cheol-In [1 ]
Huh, Kyungmin [1 ]
Cho, Sun Young [1 ]
Ha, Young Eun [1 ]
Chung, Doo Ryeon [1 ]
Peck, Kyong Ran [1 ]
机构
[1] Sungkyunkwan Univ, Div Infect Dis, Dept Med, Samsung Med Ctr,Sch Med, 81 Irwon Ro, Seoul 06531, South Korea
关键词
S; pneumoniae; levofloxacin-nonsusceptible; community-onset pneumonia; risk factor; ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; INFECTION; SUSCEPTIBILITIES; PREVALENCE; PATHOGENS; CHILDREN;
D O I
10.1089/mdr.2017.0416
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Fluoroquinolones are antibiotics commonly used in the treatment of infections caused by Streptococcus pneumoniae. However, rates of fluoroquinolone resistance are increasing with their frequent use. We designed this study to verify current fluoroquinolone resistance rates and risk factors for community-onset pneumococcal pneumonia. Methods: A retrospective case-control study was conducted in a tertiary referral hospital. The study population comprised patients admitted for pneumococcal pneumonia between January 2011 and May 2017. The case group included community-onset pneumonia caused by levofloxacin-nonsusceptible S. pneumoniae. The control group consisted of two patients with levofloxacin-susceptible S. pneumoniae who were admitted around the same time as each case. Results: A total of 198 pneumococcal pneumonia cases were identified during the study period. Twenty-five levofloxacin-resistant S. pneumoniae cases and 3 levofloxacin-intermediate S. pneumoniae cases were included in the case group (nonsusceptibility rate=14.1%). Multivariate analysis showed that healthcare-associated factors (odds ratio [OR] 4.78, 95% confidence interval [CI] 1.39-16.43, p=0.013), bronchopulmonary disease (OR 3.79, 95% CI 1.07-13.40, p=0.039), cerebrovascular disease (OR 6.08, 95% CI 1.24-29.75, p=0.026), and exposure to fluoroquinolones within the previous 3 months (OR 5.89, 95% CI 1.21-28.68, p=0.028) were associated with nonsusceptibility to levofloxacin. Conclusion: Independent risk factors for levofloxacin-nonsusceptible pneumococcal pneumonia were recent hospitalization, bronchopulmonary disease, cerebrovascular disease, and prior antibiotic use within 3 months. Careful selection of empirical antibiotics is thus needed in at-risk patients. Similarly, efforts to prevent the interpersonal spread of drug-resistant pathogens in long-term care facilities and to restrict unnecessary fluoroquinolone prescriptions are important.
引用
收藏
页码:1412 / 1416
页数:5
相关论文
共 50 条
  • [41] Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae - Comparison with Streptococcus pneumonia
    Kauppinen, MT
    Lahde, S
    Syrjala, H
    ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (16) : 1851 - 1856
  • [42] Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia
    Kays, MB
    Smith, DW
    Wack, MF
    Denys, GA
    PHARMACOTHERAPY, 2002, 22 (03): : 395 - 399
  • [43] Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae:: A case-control study
    Ho, PL
    Tse, WS
    Tsang, KWT
    Kwok, TK
    Ng, TK
    Cheng, VCC
    Chan, RMT
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) : 701 - 707
  • [44] Epidemiology of community-acquired pneumonia caused by Streptococcus pneumoniae in older adults: a narrative review
    Elias, Christelle
    Nunes, Marta C.
    Saadatian-Elahi, Mitra
    CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (02) : 144 - 153
  • [45] What Can We Learn from the Time Course of Untreated and Partially Treated Community-Onset Streptococcus pneumoniae Pneumonia? A Clinical Perspective on Superiority and Noninferiority Trial Designs for Mild Community-Acquired Pneumonia
    File, Thomas M., Jr.
    Schentag, Jerome J.
    CLINICAL INFECTIOUS DISEASES, 2008, 47 : S157 - S165
  • [46] The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae
    Yayan, Josef
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1733 - 1743
  • [47] Empiric antibiotic selection and risk prediction of drug-resistant pathogens in community-onset pneumonia
    Webb, Brandon J.
    Jones, Barbara
    Dean, Nathan C.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2016, 29 (02) : 167 - 177
  • [48] The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia
    Feldman, Charles
    Anderson, Ronald
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (06) : 806 - 818
  • [49] Macrolide-resistant Streptococcus pneumoniae in community-acquired pneumonia:: Clinical and microbiological outcomes for patients treated with levofloxacin
    Kahn, JB
    Wiesinger, BA
    Xiang, J
    CLINICAL INFECTIOUS DISEASES, 2004, 38 : S24 - S33
  • [50] Clinical manifestations and risk factors of community-onset Acinetobacter species pneumonia in Japan; case control study in a single institute in Japan
    Asai, Nobuhiro
    Sakanashi, Daisuke
    Suematsu, Hiroyuki
    Kato, Hideo
    Watanabe, Hiroki
    Shiota, Arufumi
    Hagihara, Mao
    Koizumi, Yusuke
    Yamagishi, Yuka
    Mikamo, Hiroshige
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2019, 25 (08) : 639 - 642